Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

Completed · Not applicable

Conditions studied: Gastrointestinal Cancer, Colorectal Cancer

In brief

This pilot clinical trial studies how well ultrasound works in detecting oxaliplatin-induced neuropathy in participants with gastrointestinal cancer. Ultrasound may work better in diagnosing and detecting neuropathy in gastrointestinal cancer participants treated with the chemotherapy drug called oxaliplatin.

Key facts

Study ID

NCT03958747

Run by

Wake Forest University Health Sciences

People needed

20

Starts

2019-12-17

Expected to finish

2025-11-26

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any gastrointestinal cancer including colon, rectal, colorectal, pancreas, esophageal, or other (any stage)
• Previously or currently receiving oxaliplatin -based chemotherapy.
• Clinical symptoms of peripheral neuropathy noted in medical record and suspected to be secondary to oxaliplatin -based therapy.
• Ability and willingness to understand and sign an informed consent.

You may not qualify if…

• Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of oxaliplatin chemotherapy.
• Unable to provide history.

Where it is running

• Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.